Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.

Press Release - Panoro Minerals Ltd. (PML-TSXV)

“We think that as a BDC we offer a unique opportunity for investors to not just have a potential upside by investing in a company for that company, but the ability to benefit from the portfolio companies that we invest in. We can either spin them out, distribute shares to our shareholders, or we can do a transaction where there is a sale. In addition to that, instead of waiting, which is typically the case for the one, two, three or four years for the young company to mature, we actually are able to bring our investors in where they receive shares of the public entity that owns these portfolio companies. ” - Kelly T. Hickel (Interview published July 30, 2009)    UEEC

The Most Powerful Name In Corporate News and Information.

CURRENT ISSUE COVER ARCHIVES  |  INDEX  |  CONTACT  |  FINANCIALS |  SERVICES  | HOME PAGE


CEOCFO
-
Members Login

Become A Member!



 

Epic Wound Care, Inc., a United EcoEnergy Portfolio Company, Signs Distribution Agreement With Coreva Health Science, LLC

  • Press Release
  • Source: United EcoEnergy Corp.
  • On 1:54 pm EST, Thursday December 3, 2009
    • NEW YORK, NY--(Marketwire - 12/03/09) - United EcoEnergy Corp. (OTC.BB:UEEC - News), a business development company (BDC), announced that its wholly-owned portfolio company, Epic Wound Care, Inc. has signed an international distribution agreement with Coreva Health Science LLC (Coreva) to distribute Epic's Hemostyp(TM), under the private label ActCel.
Hemostyp is an innovative gauze product designed for use on any wound where bleeding is still present. Upon contact with moisture, the gauze forms a gel-like substance that acts as a homeostatic agent to stop the bleeding quickly. Once bleeding has ceased and coagulation has occurred, the product can be rinsed away with saline solution or lukewarm water.

Epic Wound Care's Hemostyp is currently available only in limited areas around the world and the new relationship with Coreva will bring Hemostyp to a variety of new markets, principally in Europe and South America. According to Kelly Hickel, CEO of UEEC, "...this agreement opens up major new markets for Epic's state of the science critical wound care products." Special patent counsel to the project, Jennifer McCallum, Ph.D., noted that "...this was a difficult deal to close but the ultimate desire for cooperation by both parties took center stage and we are now able to take this to the next level."

Craig Bluth, CEO of Coreva, said, "We are very pleased to be part of the Epic team and a contributor to the larger goal of distributing its wound care product globally. We are currently shipping product to the Israel (professional and retail), Brazil, Chile, Australia and South Africa. We will be opening distribution in all of Europe in the near future. Our sales are growing at an exciting rate as we continue to expand distribution worldwide."

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact:


 
Contact:
Kelly T. Hickel
CEO
Telephone:  (646) 808-3095
Fax:  (212) 785-3520
Email:    Email Contact




    

ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.